Wisconsin · Nonprofit
THE AMERICAN SOCIETY OF GENE & CELL THERAPY
THE AMERICAN SOCIETY OF GENE & CELL THERAPY (Wisconsin) receives grants from 9 organizations whose IRS filings report $1,227,901 to it, the largest being CYSTIC FIBROSIS FOUNDATION ($700,000). 2 of them have funded it in more than one year.
- Revenue FY2024
- $17M
- Funders on record
- 9
- Grants received
- $1.2M
- Net assets
- $20M
What The American Society of Gene & Cell Therapy does
Mission
Asgct's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
As stated on its FY2024 Form 990.
Programs
Annual meeting: this is the primary vehicle for carrying out the educational mission of asgct. The annual meeting represents the major educational initiative of the society.
$6,234,014 spentof which $44,000 as grants$10,697,682 earned by the program53% of program spendingMolecular therapy journals: publishing scholarly journals is the second major vehicle for carrying out the educational mission of asgct. The journals are the way asgct educates and updates researchers, clinicians, and students on the latest advances in the development of novel therapeutics.
$1,042,691 spentof which $191,655 as grants$3,056,873 earned by the program9% of program spendingAdvocacy: advocacy is the third major vehicle for carrying out the educational mission of asgct. The defining value of advocacy is "gene and cell therapy will have a financial impact on patients, providers, and payers. Asgct is committed to understanding that impact and educating decision-makers engaged in developing policies that influence patient access to treatments."
$850,215 spentof which $25,000 as grants7% of program spendingOther programs include: workshops, international oncolytic virus conference, policy summit, career development program, diversity and inclusion committee, career development program patient education program, and the newsletter.
$3,553,531 spentof which $1,006,115 as grants$1,877,141 earned by the program30% of program spending
The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $11,680,451.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2021 to 2022, from $15M to $20M (+33%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
1% of THE AMERICAN SOCIETY OF GENE & CELL THERAPY’s revenue is contributions — about as donation-reliant as the typical peer (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 0 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
David Barrett
Executive director
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 1 funder to 4 funders, grant income rose $835 → $610k.
1 of 9 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 0% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of THE AMERICAN SOCIETY OF GENE & CELL THERAPY’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
THE AMERICAN SOCIETY OF GENE & CELL THERAPY leans on a few funders — its largest provides 57% of grant income and the top three 90%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
99% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund THE AMERICAN SOCIETY OF GENE & CELL THERAPY.
Largest funder’s share by year: 2017 100% · 2020 100% · 2021 100% · 2022 100% · 2023 49% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
THE AMERICAN SOCIETY OF GENE & CELL THERAPY draws 100% of its grant income from funders outside Wisconsin, across 6 states in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $132 arriving through sponsors registered in 1 state is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
THE AMERICAN SOCIETY OF GENE & CELL THERAPY runs a healthier operating margin than three-quarters of the 4,580 health nonprofits its size.
this organization peer median middle 50% of peers· 4,580 health nonprofits $10M–$100M, FY2024
Government funding THE AMERICAN SOCIETY OF GENE & CELL THERAPY receives
Grants and contracts to this organization from federal (USASpending) and state checkbooks, reconciled to its EIN. $160k on record.
- Department of Health and Human Services$160k
Federal grants vs contracts are distinguished; state line items keep their reported category. Matched by name + geography (the BMF), so coverage is partial and precision-first.
Organizations like THE AMERICAN SOCIETY OF GENE & CELL THERAPY
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Wisconsin
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
80% of spending goes to programs.
Governance
Public support
96%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Screen this organization
A dated, signed PDF of the compliance screen for THE AMERICAN SOCIETY OF GENE & CELL THERAPY: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds THE AMERICAN SOCIETY OF GENE & CELL THERAPY?
- THE AMERICAN SOCIETY OF GENE & CELL THERAPY (Wisconsin) receives grants from 9 organizations whose IRS filings report $1,227,901 to it, the largest being CYSTIC FIBROSIS FOUNDATION ($700,000). 2 of them have funded it in more than one year.
- How many funders does THE AMERICAN SOCIETY OF GENE & CELL THERAPY have?
- IRS filings report 9 organizations giving $1,227,901 in grants to THE AMERICAN SOCIETY OF GENE & CELL THERAPY, 2 of which have funded it in more than one year.
- Who is the largest funder of THE AMERICAN SOCIETY OF GENE & CELL THERAPY?
- CYSTIC FIBROSIS FOUNDATION is the largest funder on record, with $700,000 in grants. The full list of funders is on this page.
- How can an organization like THE AMERICAN SOCIETY OF GENE & CELL THERAPY find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Wisconsin. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 9 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing